

PharmaForum 2010, am 3. November in Mainz

1. Company

TRION Pharma GmbH is a privately held biopharmaceutical company that has established a novel approach to cancer immunotherapy. The Company's unique family of trifunctional therapeutic antibodies, called Triomab[®], simultaneously activates multiple immune defense mechanisms against cancer. TRION employs about 100 people in Munich for development and cGMP-manufacturing of its antibody products.

2. Core Competences

The antibody anti-EpCAM x anti-CD3 Removab[®] (catumaxomab) is the most advanced product of the Triomab[®] family developed in collaboration with Fresenius Biotech GmbH. Generally, these Triomab[®] antibodies including Removab[®] bind to tumor-associated antigens and recruit T cells as well as accessory cells to the tumor site resulting in a new quality of highly efficient tumor cell killing at more than 1.000-fold reduced dose-response relationship than in case of conventional therapeutic antibodies. Since spring 2009, Removab[®] is approved in the EU for the intraperitoneal treatment of malignant ascites in patients with EpCAM-positive carcinomas. Of note, Removab[®] is not only the first drug indicated for the treatment of malignant ascites, but also the first approved bispecific, trifunctional antibody worldwide.

3. Cooperations offered and requested

TRION seeks strategic partnering opportunities in the field of therapeutic antibody development.